Stock listing
Frankfurt:26CA ImmunityBio, Inc. Aktie
German listing (Frankfurt) of ImmunityBio, Inc. · home listing NASDAQ:IBRX
Follow ImmunityBio, Inc. into a list and get an email when it puts out news.
Share price · FWB:26CA
€5.51 EUR -0.45 (-7.6%)
Close on Nov 20, 2026
- Day range
- €5.51 – €5.86 EURNov 20, 2026
- Market cap
- €5.84B EURAt the close on Nov 20, 2026 · price × 1.06B shares outstanding
- 52-week range
- €1.70 – €10.46 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €26,817 EURMedian day 500 shares · 16 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:IBRX · Home | $6.02 USD | -0.68 (-10.1%) | 10,565,228 | $6.41 | $6.53 | $6.00 | $6.70 | Close on Nov 20, 2026 |
| Frankfurt:26CA | €5.51 EUR | -0.45 (-7.6%) | — | €5.86 | €5.86 | €5.51 | €5.96 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:26CA · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €7.705 | +0.55 | +7.7% | €7.187 | €7.768 | €7.179 | 0 | |
| €7.155 | -0.714 | -9.1% | €7.803 | €7.883 | €7.088 | 13,482 | |
| €7.869 | +0.521 | +7.1% | €7.361 | €7.922 | €7.333 | 200 | |
| €7.348 | +0.195 | +2.7% | €7.085 | €7.396 | €7.081 | 400 | |
| €7.153 | -0.262 | -3.5% | €7.314 | €7.438 | €7.085 | 0 | |
| €7.415 | -0.313 | -4.1% | €7.605 | €7.673 | €7.262 | 15,968 | |
| €7.728 | -0.046 | -0.6% | €7.822 | €7.847 | €7.613 | 12,664 | |
| €7.774 | +0.122 | +1.6% | €7.743 | €7.778 | €7.711 | 35,952 | |
| €7.652 | +0.644 | +9.2% | €7.039 | €7.656 | €7.035 | 1,600 | |
| €7.008 | -0.282 | -3.9% | €7.234 | €7.235 | €6.97 | 1,600 | |
| €7.29 | -0.109 | -1.5% | €7.202 | €7.336 | €7.199 | 24,424 | |
| €7.399 | -0.273 | -3.6% | €7.481 | €7.625 | €7.197 | 0 | |
| €7.672 | -0.222 | -2.8% | €7.813 | €7.964 | €7.508 | 9,270 | |
| €7.894 | +0.344 | +4.6% | €7.403 | €7.937 | €7.379 | 1,220 | |
| €7.55 | -0.636 | -7.8% | €8.16 | €8.509 | €7.543 | 0 | |
| €8.186 | -0.694 | -7.8% | €8.927 | €9.04 | €8.173 | 0 | |
| €8.88 | +0.005 | +0.1% | €8.864 | €9.037 | €8.806 | 540 | |
| €8.875 | +0.153 | +1.8% | €8.717 | €9.287 | €8.422 | 12 | |
| €8.722 | -0.422 | -4.6% | €8.977 | €9.093 | €8.693 | 175 | |
| €9.144 | -0.244 | -2.6% | €9.385 | €9.389 | €9.07 | 1,086 | |
| €9.388 | +0.673 | +7.7% | €8.834 | €9.548 | €8.827 | 10,000 | |
| €8.715 | +0.098 | +1.1% | €8.665 | €8.832 | €8.605 | 458 | |
| €8.617 | +0.01 | +0.1% | €8.572 | €8.739 | €8.309 | 0 | |
| €8.607 | -0.572 | -6.2% | €9.197 | €9.298 | €8.58 | 90 | |
| €9.179 | +0.081 | +0.9% | €9.278 | €9.44 | €9.097 | 4,375 | |
| €9.098 | +0.839 | +10.2% | €8.152 | €9.278 | €8.146 | 1,393 | |
| €8.259 | -0.183 | -2.2% | €8.398 | €8.417 | €8.071 | 145 | |
| €8.442 | +0.754 | +9.8% | €7.746 | €8.768 | €7.725 | 1,180 | |
| €7.688 | +0.215 | +2.9% | €7.463 | €7.847 | €7.419 | 0 | |
| €7.473 | -0.028 | -0.4% | €7.386 | €7.741 | €7.335 | 0 | |
| €7.501 | -0.094 | -1.2% | €7.582 | €7.582 | €7.34 | 1,900 | |
| €7.595 | -0.10 | -1.3% | €7.494 | €7.609 | €7.336 | 1,665 | |
| €7.695 | -0.485 | -5.9% | €8.097 | €8.132 | €7.614 | 500 | |
| €8.18 | +0.822 | +11.2% | €7.295 | €8.183 | €7.292 | 500 | |
| €7.358 | +0.028 | +0.4% | €7.372 | €7.553 | €7.176 | 0 | |
| €7.33 | -0.118 | -1.6% | €7.293 | €7.367 | €7.276 | 2,193 | |
| €7.448 | +0.55 | +8.0% | €6.895 | €7.621 | €6.855 | 970 | |
| €6.898 | -0.031 | -0.4% | €6.943 | €7.123 | €6.877 | 930 | |
| €6.929 | -0.194 | -2.7% | €7.16 | €7.162 | €6.844 | 0 | |
| €7.123 | +0.109 | +1.6% | €6.733 | €7.229 | €6.721 | 100 | |
| €7.014 | +0.356 | +5.3% | €6.733 | €7.07 | €6.701 | 21,046 | |
| €6.658 | -0.285 | -4.1% | €6.832 | €6.852 | €6.556 | 0 | |
| €6.943 | -0.157 | -2.2% | €6.983 | €7.053 | €6.865 | 10,033 | |
| €7.10 | +0.319 | +4.7% | €6.801 | €7.216 | €6.773 | 0 | |
| €6.781 | -0.172 | -2.5% | €6.757 | €6.785 | €6.749 | 44 | |
| €6.953 | -0.065 | -0.9% | €7.05 | €7.08 | €6.939 | 4,400 | |
| €7.018 | +0.14 | +2.0% | €6.792 | €7.068 | €6.751 | 0 | |
| €6.878 | +0.111 | +1.6% | €6.783 | €6.94 | €6.638 | 0 | |
| €6.767 | -0.045 | -0.7% | €6.817 | €6.835 | €6.652 | 200 | |
| €6.812 | -0.132 | -1.9% | €6.835 | €6.882 | €6.785 | 1,779 | |
| €6.944 | -0.371 | -5.1% | €7.118 | €7.204 | €6.837 | 1,779 | |
| €7.315 | +0.178 | +2.5% | €7.034 | €7.377 | €7.003 | 10,000 | |
| €7.137 | +0.165 | +2.4% | €6.997 | €7.15 | €6.984 | 2,960 | |
| €6.972 | +0.432 | +6.6% | €6.451 | €7.009 | €6.442 | 0 | |
| €6.54 | -0.107 | -1.6% | €6.734 | €6.759 | €6.426 | 150 | |
| €6.647 | -0.07 | -1.0% | €6.636 | €6.779 | €6.632 | 5,428 | |
| €6.717 | -0.239 | -3.4% | €6.907 | €6.985 | €6.625 | 0 |
- Ticker
- Frankfurt:26CA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 19, 2026
ImmunityBio Named No. 2 Fastest-Growing Technology Company in North America on the 2026 Deloitte Technology Fast 500™
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 33 slides
Latest news
ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer
Oct 21, 2026
Closed €7.67 (-2.8%) on Oct 21, 2026
ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors
Oct 16, 2026
Closed €7.55 (-7.8%) on Oct 19, 2026
FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
Oct 14, 2026
Closed €8.88 (+0.1%) on Oct 15, 2026
ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium
Oct 8, 2026
Closed €8.72 (+1.1%) on Oct 8, 2026
ImmunityBio, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 54 in the last 12 months · 210 in all · newest Nov 19, 2026 · oldest 2019
- Decks
- 10 decks · latest August 2026
Where ImmunityBio, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:IBRX · Home listing | NASDAQ | United States | USD |
| gettex:26CA | gettex | Germany | EUR |
| LS Exchange:A2QQ2E | LS Exchange | Germany | EUR |
| Tradegate:26CA | Tradegate | Germany | EUR |
| BOATS:IBRX | BOATS | United States | USD |
| Frankfurt:26CA · This page | Frankfurt | Germany | EUR |
| Lang & Schwarz:A2QQ2E | Lang & Schwarz | Germany | EUR |
| Dusseldorf:26CA | Dusseldorf | Germany | EUR |
| Stuttgart:26CA | Stuttgart | Germany | EUR |
| Munich:26CA | Munich | Germany | EUR |
| Hamburg:26CA | Hamburg | Germany | EUR |
| Hanover:26CA | Hanover | Germany | EUR |
| Xetra:26CA | Xetra | Germany | EUR |
| BMV:IBRX | BMV | Mexico | MXN |
Valuation
EV/sales 33.4× against a median of 56.2×: 4th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $6.10B USD
- P/E
- Loss
- EV/sales
- 33.4×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 96.7%
- Operating margin
- −150.2%
- Net margin
- −607.8%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.50
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| ImmunityBio, Inc. · NASDAQ:IBRX | US$6.40B | US$6.10B | n/a | 33.4× | n/a | n/a | −607.8% | n/a | 1.50 |
| CG Oncology, Inc. · NASDAQ:CGON | US$7.10B | US$6.12B | n/a | 992× | n/a | 7.2× | n/a | 0.0× | 0.83 |
| Cytokinetics, Incorporated · NASDAQ:CYTK | US$7.07B | US$6.36B | n/a | 56.2× | n/a | n/a | −686.6% | n/a | 0.93 |
| Axsome Therapeutics, Inc. · NASDAQ:AXSM | US$6.80B | US$6.68B | n/a | 7.7× | n/a | 64.5× | −18.2% | 1.8× | 0.69 |
| Akeso, Inc. · HKEX:9926 | US$6.66B | US$6.04B | n/a | 13.5× | n/a | 5.2× | −36.4% | 0.6× | n/a |
| Immunovant, Inc. · NASDAQ:IMVT | US$6.57B | US$5.85B | n/a | 825× | n/a | 10.0× | n/a | 0.0× | 1.46 |
| Oruka Therapeutics, Inc. · NASDAQ:ORKA | US$6.50B | US$5.58B | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.30 |
| Kodiak Sciences Inc · NASDAQ:KOD | US$6.35B | US$6.31B | n/a | n/a | n/a | 505× | n/a | 3.7× | 1.58 |
| Abivax SA · EURONEXT:ABVX | US$6.05B | US$5.60B | n/a | n/a | n/a | 15.1× | n/a | 0.0× | n/a |
| Scholar Rock Holding Corporation · NASDAQ:SRRK | US$5.87B | US$5.65B | n/a | 9,921× | n/a | 34.8× | n/a | 1.2× | 0.91 |
| Arrowhead Pharmaceuticals, Inc. · NASDAQ:ARWR | US$5.85B | US$4.66B | n/a | 10.3× | n/a | 116× | −160.6% | 0.0× | 1.34 |
| Median of the others | US$6.54B | US$5.95B | 56.2× | 15.1× | −98.5% | 0.0× | 1.12 |
Forecasts
3 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 14.25 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.93 · 1 analyst
- Revenue, year to Dec 2026
- 201.8M · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Rich Adcock | President & Chief Executive Officer |
| David Sachs | Chief Financial Officer |
| Hemanth Ramaprakash | Investor Relations |
| Bruce Brown | Senior Vice President, Medical Affairs |
| Charles G. Garlisi | Senior Vice President, Regulatory Affairs |
| Elizabeth Gabitzsch | Senior Vice President, Product Development & Vaccine Programs |
| Emily Arison | Senior Vice President of Human Resources |
| Manju Saxena | Senior Vice President of Product Development, Cell Therapy Program |
| Barry Simon | Chief Corporate Affairs Officer |
| Enrique Diloné | Chief Technology Officer |
| Leonard S. Sender | Chief Medical Officer, Liquid Tumors & Cell Therapy |
| Matthew Hilman | Vice President US Commercial – Urologic Oncology |
| Patrick Soon-Shiong | Executive Chairman of the Board |
| Regan Lauer | Chief Accounting Officer |
| Sandeep Bobby Reddy | Chief Medical Officer |
| Sarah Singleton | Chief Communications Officer & Head of Patient Advocacy |
Board
| Director | Role |
|---|---|
| Jim Yong Kim | Vice Chairman |
| Patrick Soon-Shiong | Executive Chairman of the Board |
| Bruce Wendel | |
| Cheryl Cohen | |
| Christobel Selecky | |
| Linda Maxwell | |
| Michael Blaszyk | |
| Wesley Clark |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · Before open | −17.7% |
| Q2 2026 | Aug 4, 2026 · Before open | −2.8% |
| Q1 2026 | May 7, 2026 · Before open | −7.4% |
| Q4 2025 | Mar 3, 2026 | −13.8% |
| Q3 2025 | Nov 4, 2025 · After close | +3.4% |
| Q2 2025 | Aug 5, 2025 · Before open | 0.0% |
| Q1 2025 | May 7, 2025 · After close | +10.6% |
| Q4 2024 | Mar 3, 2025 · Before open | −13.4% |
| Q3 2024 | Nov 12, 2024 · Before open | −9.2% |
| Q2 2024 | Aug 12, 2024 · Before open | −2.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | +0.7% |
| Q4 2023 | Mar 19, 2024 · After close | +10.3% |
| Q3 2023 | Nov 9, 2023 · Before open | −17.1% |
| Q2 2023 | Aug 8, 2023 · After close | −10.2% |
| Q1 2023 | May 11, 2023 · Before open | −55.1% |
| Q4 2022 | Mar 1, 2023 · After close | −10.6% |
| Q3 2022 | Nov 9, 2022 · Before open | −10.7% |
| Q2 2022 | Aug 8, 2022 · After close | −2.9% |
| Q1 2022 | May 10, 2022 · After close | −22.3% |
| Q4 2021 | Mar 1, 2022 · After close | −1.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 33 slides | August 2026 |
| Milken Institute Presentation 2026 | Conference | 67 slides | Feb 24, 2026 |
| Investor Presentation (November 2022) | Investor deck | 30 slides | Nov 15, 2022 |
| Jefferies Healthcare Conference 2022 | Conference | 32 slides | Jun 10, 2022 |
| Investor Presentation (June 2021) | Investor deck | 58 slides | Jun 4, 2021 |
| Investor Presentation (March 2021) | Investor deck | 45 slides | Mar 17, 2021 |
| 39th Annual JP Morgan Healthcare Conference 2021 | Conference | 35 slides | Jan 13, 2021 |
| NantKwest — Merger or Acquisition (December 2020) | Merger or acquisition | 31 slides | Dec 21, 2020 |
| LifeSci Advisors Investor Call, May 27, 2020 | Conference | 18 slides | May 27, 2020 |
| NantKwest — Investor Day (December 2019) | Investor day | 111 slides | Dec 2, 2019 |
Financings
| Raise | Date |
|---|---|
| Registered direct offering of common stock and warrants Announced: about US$80M · Piper Sandler & Co. Dealers: Piper Sandler & Co. (lead) Use of proceeds: Further working capital and support for ongoing business operations | Jul 25, 2025 |
| Registered direct offering of common stock and warrants Announced: about US$75M · warrants for the purchase of additional shares of common stock; if fully exercised,… Buyers: single institutional investor Use of proceeds: Working capital and ongoing business operations | Apr 8, 2025 |
| Public offering of common stock Update: about US$100M · US$3 a share · Jefferies +4 Dealers: Jefferies (co-lead), Piper Sandler (co-lead), BTIG (co-lead), H.C. Wainwright & Co. (co-lead), D. Boral Capital Use of proceeds: Commercialization of ANKTIVA for bladder cancer, trials in BCG-naive NMIBC and NSCLC, R&D, working capital and general corporate purposes | Dec 11, 2024 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as NantKwest, Inc. Priced at US$25.00 a share on Jul 27, 2015.
- Price
- US$25.00 a share
- Shares offered
- 8,288,000 shares of common stock
- Offering size
- US$207.2 million
- Underwriters' option
- Up to 1,243,200 more shares
- Underwriters
- BofA Merrill Lynch, Citigroup, Jefferies, Piper Jaffray, MLV & Co. · In the order on the cover
- Shares delivered
- On or about Jul 31, 2015
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 14, 2015 |
| Filed publicly | Jun 19, 2015 |
| Amended 6 times | Newest Jul 27, 2015 |
| Shares registered with an exchange | Jul 20, 2015 |
| Declared effective by the SEC | Jul 27, 2015 |
| Final prospectus, with the price | Jul 29, 2015 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 29, 2015 |
| EFFECT · Notice that a registration is effective | Jul 27, 2015 |
| S-1MEF · Registration of more shares for the same offering | Jul 27, 2015 |
| S-1/A · Registration statement, amended | Jul 27, 2015 |
| S-1/A · Registration statement, amended | Jul 27, 2015 |
| CERTNAS · Nasdaq's certificate of listing | Jul 24, 2015 |
| CORRESP · Letter to the SEC | Jul 24, 2015 |
| CORRESP · Letter to the SEC | Jul 24, 2015 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 20, 2015 |
| S-1/A · Registration statement, amended | Jul 16, 2015 |
All 23 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jul 15, 2015 |
| S-1/A · Registration statement, amended | Jul 15, 2015 |
| CORRESP · Letter to the SEC | Jul 13, 2015 |
| S-1/A · Registration statement, amended | Jul 13, 2015 |
| UPLOAD · Letter from the SEC | Jul 10, 2015 |
| CORRESP · Letter to the SEC | Jul 6, 2015 |
| CORRESP · Letter to the SEC | Jul 2, 2015 |
| S-1/A · Registration statement, amended | Jul 2, 2015 |
| UPLOAD · Letter from the SEC | Jun 26, 2015 |
| CORRESP · Letter to the SEC | Jun 19, 2015 |
| S-1 · Registration statement | Jun 19, 2015 |
| UPLOAD · Letter from the SEC | Jun 10, 2015 |
| DRS · Draft registration statement | May 14, 2015 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 29, 2015
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 113.3M | 14.7M | 622.0K | 240.0K | 934.0K | 605.0K | 2.20M | 47.0K | 45.0K | 44.0K |
| Cost of revenue | 753.0K | 0 | 0 | 0 | 9.15M | 9.01M | -3.11M | |||
| Gross profit | 112.5M | 14.7M | 622.0K | 240.0K | 934.0K | 605.0K | -8.97M | 3.16M | 45.0K | 44.0K |
| Research and development | 207.9M | 190.1M | 232.4M | 248.1M | 196.0M | 139.5M | 112.0M | 55.7M | 42.0M | 29.2M |
| Selling, general and administrative | 150.0M | 168.8M | 129.6M | 102.7M | 135.3M | 71.3M | 46.5M | 42.7M | 57.1M | 95.4M |
| Operating income | -256.0M | -344.2M | -362.3M | -351.3M | -330.3M | -220.9M | -156.3M | -98.4M | -99.1M | -124.5M |
| Depreciation and amortization | 15.5M | 17.6M | 18.5M | 18.3M | 14.2M | 12.7M | 14.0M | 9.55M | 5.57M | 3.61M |
| EBITDA | -240.5M | -326.6M | -343.7M | -333.0M | -316.0M | -208.1M | -142.2M | -88.8M | -93.6M | -120.9M |
| Interest expense | 60.9M | 114.6M | 128.8M | 63.5M | 14.8M | 9.07M | 5.92M | 433.0K | 618.0K | 66.0K |
| Income before tax | -351.6M | -413.6M | -583.9M | -417.3M | -349.8M | -226.0M | -160.3M | -96.7M | -96.9M | -121.4M |
| Income tax | -135.0K | 0 | -40.0K | 34.0K | 9.00K | -1.85M | -105.0K | -503.0K | -493.0K | -572.0K |
| Net income | -351.4M | -413.6M | -583.2M | -416.6M | -346.8M | -221.9M | -157.8M | -96.2M | -96.4M | -120.8M |
| Earnings per share, basic | -0.38 | -0.59 | -1.15 | -1.04 | -0.89 | -0.59 | -0.43 | -1.22 | -1.20 | -1.47 |
| Earnings per share, diluted | -0.38 | -0.62 | -1.15 | -1.04 | -0.89 | -0.59 | -0.43 | -1.22 | -1.20 | -1.47 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 88.3M | 143.4M | 265.5M | 104.6M | 181.1M | 34.9M | 75.8M | 16.8M | 23.9M | 8.08M |
| Short-term investments | 154.5M | 6.38M | 1.01M | 2.54M | 136.0M | 61.1M | 36.1M | 57.3M | 104.3M | 190.8M |
| Receivables | 42.6M | 2.36M | 0 | 1.89M | 1.33M | 2.00M | 303.0K | 12.2M | 1.26M | 2.67M |
| Inventory | 910.0K | 8.27M | 0 | 26.4M | 1 | |||||
| Current assets | 314.9M | 184.6M | 294.1M | 140.6M | 334.3M | 111.7M | 55.8M | 88.8M | 132.5M | 205.1M |
| Property, plant and equipment | 114.3M | 137.1M | 146.1M | 143.7M | 82.9M | 72.5M | 60.5M | 76.9M | 76.7M | 18.9M |
| Goodwill | 910.0K | 910.0K | ||||||||
| Total assets | 501.9M | 382.9M | 504.5M | 362.4M | 468.9M | 221.4M | 143.1M | 181.9M | 250.4M | 317.5M |
| Accounts payable | 6.98M | 6.72M | 9.20M | 21.0M | 11.4M | 11.5M | 1.75M | 2.79M | 5.87M | 4.04M |
| Current liabilities | 61.8M | 54.9M | 58.3M | 500.9M | 369.0M | 68.1M | 11.6M | 27.3M | 20.9M | 12.6M |
| Long-term debt | 477.1M | 461.9M | 681.5M | 241.3M | 306.3M | 254.4M | ||||
| Total debt | 878.1M | 504.2M | 726.7M | 723.8M | 645.7M | 275.5M | 14.8M | 6.91M | 7.27M | 8.21M |
| Total liabilities | 1.00B | 871.1M | 1.09B | 812.2M | 712.8M | 339.9M | 22.4M | 35.9M | 31.6M | 24.1M |
| Shareholders' equity | -500.5M | -489.1M | -587.0M | -447.3M | -242.2M | -119.8M | 120.7M | 146.0M | 218.8M | 293.4M |
| Shares outstanding | 1.01B | 852.9M | 670.9M | 421.6M | 397.8M | 382.2M | 98.5M | 79.1M | 79.0M | 82.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -304.9M | -391.2M | -366.8M | -337.5M | -274.4M | -171.7M | -152.1M | -63.4M | -48.8M | -38.6M |
| Capital spending | -3.85M | -6.89M | -30.6M | -78.2M | -33.6M | -1.67M | -4.29M | -13.1M | -34.8M | -6.56M |
| Free cash flow | -308.8M | -398.1M | -397.3M | -415.7M | -308.0M | -173.4M | -156.4M | -76.5M | -83.6M | -45.2M |
| Cash from investing | -149.8M | -12.2M | -30.5M | 27.3M | -84.9M | -19.8M | 18.6M | 57.1M | 99.6M | -113.7M |
| Cash from financing | 400.2M | 281.6M | 558.3M | 233.6M | 505.4M | 150.7M | 114.3M | -771.0K | -35.0M | -15.6M |
| Dividends paid | -616.0K | -334.4M | -4.44M | -2.28M | ||||||
| Share buybacks | -3.44M | -616.0K | 0 | 0 | -2.50M | -228.0K | -15.2M | -15.8M | ||
| Change in cash | -54.5M | -121.9M | 160.8M | -76.3M | 146.2M | -40.9M | -19.3M | -7.05M | 15.8M | -167.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| 8-K · Current report | Nov 9, 2026 | Current report | SEC |
| 8-K · Current report | Oct 14, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 2, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 6, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 4, 2026 | Quarterly report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Aug 4, 2026 | Results | SEC |
| 8-K · Current report | Jul 30, 2026 | Current report | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 30, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 29, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 10, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| 8-K · Current report | May 18, 2026 | Material contract | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 29, 2026 | Annual report | SEC |
| 8-K · Current report | Apr 9, 2026 | Results | SEC |
| 8-K · Current report | Apr 6, 2026 | Current report | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 31, 2026 | Material contract | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 25, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 10-K · Annual report | Feb 23, 2026 | Annual report | SEC |
| 144 · Notice of proposed sale | Feb 23, 2026 | Other filings | SEC |
| 8-K · Current report | Feb 23, 2026 | Results | SEC |
| 8-K · Current report | Feb 18, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 26, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 16, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 15, 2026 | Results | SEC |
| 8-K · Current report | Jan 14, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Dec 23, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Dec 23, 2025 | Offer document | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 15, 2025 | Management or board change | SEC |
| 8-K · Current report | Dec 12, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 10, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 4, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2025 | Results | SEC |
| DEF 14C | Oct 20, 2025 | Meeting notice | SEC |
| PRE 14C | Oct 8, 2025 | Meeting notice | SEC |
| 8-K · Current report | Aug 8, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2025 | Results | SEC |
| 424B5 · Prospectus | Jul 28, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 25, 2025 | Results | SEC |
| S-8 · Registration statement for employee plans | Jun 23, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 20, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2025 | Results | SEC |
| 8-K · Current report | May 5, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 15, 2025 | Results | SEC |
| 424B5 · Prospectus | Apr 8, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 8, 2025 | Material contract | SEC |
| 8-K · Current report | Mar 19, 2025 | Current report | SEC |
| 10-K · Annual report | Mar 3, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 3, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 12, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Feb 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 7, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2024 | Insider trade | SEC |
| 424B5 · Prospectus | Dec 12, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 11, 2024 | Material contract | SEC |
| 8-K · Current report | Dec 10, 2024 | Current report | SEC |
| 424B5 · Prospectus | Dec 10, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 19, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jul 17, 2024 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Jun 20, 2024 | Offer document | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2024 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | May 3, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 30, 2024 | Other filings | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 29, 2024 | Annual report | SEC |
| 8-K · Current report | Apr 23, 2024 | Current report | SEC |
| S-3ASR · Registration statement | Apr 17, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Apr 3, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 28, 2024 | Other filings | SEC |
| S-3 · Registration statement | Mar 28, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 19, 2024 | Annual report | SEC |
| 4 · Change in ownership | Feb 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 23, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Feb 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Jan 3, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 2, 2024 | Material contract | SEC |
| 4 · Change in ownership | Dec 19, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 8, 2023 | Quarterly report | SEC |
| DEF 14C | Sep 28, 2023 | Meeting notice | SEC |
| D | Sep 22, 2023 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 21, 2023 | Big-stake notice | SEC |
| PRE 14C | Sep 15, 2023 | Meeting notice | SEC |
| 4 · Change in ownership | Sep 13, 2023 | Insider trade | SEC |
| 8-K · Current report | Sep 11, 2023 | Material contract | SEC |
| 4 · Change in ownership | Sep 6, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 6, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 6, 2023 | Insider trade | SEC |
| 8-K · Current report | Sep 1, 2023 | Current report | SEC |
| 4 · Change in ownership | Aug 28, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2023 | Insider trade | SEC |
| 8-K · Current report | Aug 15, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Aug 8, 2023 | Quarterly report | SEC |
| 424B5 · Prospectus | Jul 25, 2023 | Offer document | SEC |
| 424B5 · Prospectus | Jul 24, 2023 | Offer document | SEC |
| 8-K · Current report | Jul 21, 2023 | Material contract | SEC |
| 8-K · Current report | Jul 20, 2023 | Current report | SEC |
| 4 · Change in ownership | Jun 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 14, 2023 | Material contract | SEC |
| 4 · Change in ownership | Jun 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | May 22, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | May 16, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | May 11, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2023 | Current report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2023 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 28, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2023 | Material contract | SEC |
This page holds 200 of 557 filings. Open Filings
Cap table
Built by 6ix from ImmunityBio, Inc.’s releases · as of Nov 3, 2026
- Common shares
- 1,063,826,073
- Fully diluted
- 1,063,826,073
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 1,063,826,073 | Nov 3, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 3, 2026 | 1,063,826,073 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Steve Gorlin Other companies: BioVie Inc. (Director · Jun 30, 2020 – Nov 9, 2023 · Past); PolarityTE Inc. (Director · Feb 8, 2017 – Aug 6, 2019 · Past); Catasys Inc (Director · Nov 6, 2014 – Jun 15, 2018 · Past); DARA Biosciences Inc (Director · Feb 12, 2008 – May 15, 2012 · Past); MiMedx Group, Inc (Director · Feb 8, 2008 – May 16, 2013 · Past); Medivation Inc (Director · Dec 31, 2005 – Dec 31, 2005 · Past) | Director · Jul 27, 2015 – Jun 10, 2020 · Past |
| John C. Thomas Other companies: Dogwood Therapeutics, Inc. (Director · Since at least Dec 16, 2020); Novelion Therapeutics Inc (Director · Jun 4, 2012 – Aug 9, 2018 · Past); DARA Biosciences Inc (Director · Feb 12, 2008 – Feb 14, 2012 · Past); MiMedx Group, Inc (CFO & Secretary · Feb 8, 2008 – Feb 8, 2008 · Past) | Director · Jul 27, 2015 – Dec 10, 2020 · Past |
| Bruce Wendel Other companies: GT Biopharma, Inc. (Director · Nov 11, 2020 – Jan 27, 2023 · Past); Verastem, Inc. (Director · Jun 14, 2016 – Jun 16, 2020 · Past); Abraxis BioScience Inc (Chief Executive Officer, Director · Nov 7, 2007 – Oct 15, 2010 · Past) | Director · Since at least Dec 12, 2025 |
| Barry Simon Other companies: Viracta Therapeutics Inc (Director · Mar 3, 2021 – Jun 20, 2024 · Past); Cue Biopharma, Inc. (Director · Jan 4, 2021 – Jan 4, 2021 · Past) | Director · Since at least Dec 22, 2020 |
| Michael Blaszyk Other companies: Nanthealth LLC (Director · Jun 1, 2016 – Jun 9, 2022 · Past); APP Pharmaceuticals Inc (Director · Aug 1, 2006 – Sep 10, 2008 · Past) | Director · Since at least Jul 27, 2015 |
| Robert Rosen Other companies: La Jolla Pharmaceutical Co (Director · Jul 7, 2014 – Aug 22, 2022 · Past); Heron Therapeutics, Inc. (President, Director · May 1, 2013 – Dec 15, 2018 · Past) | Director · Jul 27, 2015 – Jul 27, 2015 · Past |
| Sonja Nelson Other companies: Ambrx Biopharma Inc. (Chief Financial Officer · Jan 1, 2023 – Mar 7, 2024 · Past); Motus GI Holdings, Inc. (Director · Jun 22, 2021 – Mar 5, 2024 · Past) | Chief Financial Officer · Aug 2, 2019 – Jan 12, 2021 · Past |
| Cheryl L. Cohen Other companies: Celldex Therapeutics, Inc. (Director · Since at least Jun 13, 2024) | Director · Since at least Jun 11, 2024 |
| Linda Maxwell Other companies: United Therapeutics Corporation (Director · Since at least Jul 8, 2021) | Director · Since at least Mar 29, 2021 |
| Regan Lauer Other companies: Banc of California, Inc. (SVP - CONTROLLER · Dec 31, 2008 – Oct 23, 2012 · Past) | Chief Accounting Officer · Since at least Nov 9, 2021 |
All 32 people
| Person | Seat |
|---|---|
| Richard J Tajak Other companies: APP Pharmaceuticals Inc (Exec. VP & CFO · Apr 29, 2008 – Sep 10, 2008 · Past) | Chief Financial Officer · Jan 20, 2016 – Mar 23, 2017 · Past |
| Wesley Clark Other companies: Blue Acquisition Corp. (Director · Since at least Jun 12, 2025) | Director · Since at least Jun 14, 2022 |
| Bruce Brown | Senior Vice President, Medical Affairs · Since at least Apr 21, 2025 |
| Charles G. Garlisi | Senior Vice President, Regulatory Affairs · Since at least Nov 5, 2026 |
| Christobel Selecky | Director · Since at least Jun 29, 2026 |
| David Sachs | Chief Financial Officer · Since at least Nov 5, 2026 |
| Elizabeth Gabitzsch | Senior Vice President, Product Development & Vaccine Programs · Since at least Nov 5, 2026 |
| Emily Arison | Senior Vice President of Human Resources · Since at least Nov 5, 2026 |
| Enrique Diloné | Chief Technology Officer · Since at least Nov 5, 2026 |
| Hemanth Ramaprakash | Investor Relations · Since at least May 7, 2026 |
| Jim Yong Kim | Vice Chairman · Since Aug 10, 2026 · Appointed, no departure found |
| Jim Yong Kim | Vice Chairman · Since at least Aug 10, 2026 |
| John Owen Brennan | Director · Mar 9, 2021 – Jun 11, 2024 · Past |
| Leonard S. Sender | Chief Medical Officer, Liquid Tumors & Cell Therapy · Since at least Nov 5, 2026 |
| Manju Saxena | Senior Vice President of Product Development, Cell Therapy Program · Since at least Nov 5, 2026 |
| Matthew Hilman | Vice President US Commercial – Urologic Oncology · Since at least Nov 5, 2026 |
| Patrick Soon-Shiong | Executive Chairman of the Board · Since at least Oct 21, 2026 |
| Rich Adcock | President & Chief Executive Officer · Since at least Jan 14, 2026 |
| Richard Adcock | CEO & President, Director · Since at least Dec 31, 2023 |
| Richard Kusserow | Director · Jun 9, 2017 – Jun 9, 2017 · Past |
| Sandeep Bobby Reddy | Chief Medical Officer · Since at least Apr 21, 2025 |
| Sarah Singleton | Chief Communications Officer & Head of Patient Advocacy · Since at least Oct 8, 2026 |
Log in to ask 6ix AI your own questions about ImmunityBio, Inc.